Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
haiscorubritinib
- Development stage
- Phase 1
- Lead developer
- HitGen
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
haiscorubritinib (HG030) is a novel, second-generation small-molecule tyrosine kinase inhibitor developed by HitGen, Inc. It is designed to target and inhibit Neurotrophic tyrosine kinase receptor (NTRK) and Proto-oncogene tyrosine-protein kinase ROS (ROS1) fusion proteins. This drug is being investigated for the treatment of locally advanced or metastatic solid tumors that harbor NTRK and ROS1 gene fusions. It is particularly noted for its potential to overcome acquired resistance to first-generation Trk inhibitors, demonstrating favorable drug-like properties and significant antitumor activity in preclinical studies.
02
Targets
NTRK1 (Tropomyosin-related receptor kinase A)NTRK2 (Tropomyosin-related kinase receptor type B)NTRK3 (Tropomyosin receptor kinase C)ROS1 (Proto-oncogene tyrosine-protein kinase ROS)
Beyond the preview
Go deeper on haiscorubritinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on haiscorubritinib.